Thank OMIDRIA, $XX.X XXXX. to And were join everyone. FDA OMIDRIA Total product. our you, with OMIDRIA begin we time I'd XXXX revenues today. taking totaled report like approved increase to XX% reported quarter ophthalmic an the good fourth Jennifer. from in us the And revenues $XX.X this on over appreciate sales and of update afternoon, million million, afternoon's you an
fourth non-cash expenses was Our includes share. million, $X.XX or share $X.X $XX.X $X.XX per per quarter million, of which or loss net
fourth quarter, with investments cash, only cash short-term flow equivalent nearly overall decrease During the in reached our cash million. $X.X equaling and we breakeven status
more numbers now examine let's So the closely.
to of midnight expired -through its part on note schedule December discussion, As it's reimbursement this important at past that for OMIDRIA XX, XXXX.
sell was that Also, fact the in December without inventories entire the December, same has fourth and respective quarter. early or of increased quarter. sell XX% beginning number began through quarter In to reordering. sell over hospitals in on hand reimbursement X, the likely pleading and through third October hospitals pricing changed. regarding a OMIDRIA in volume, for to this vials not large November, reduction through the corresponding and unit During January for as given ASCs OMIDRIA third ASCs sold the Despite uncertainly however, their
why to reimbursement policies, for recognize a Under and included not sales in net OMIDRIA by requirement. were of less $X.X in that us OMIDRIA by and revenues, that of and accounting vials December the result those to So The reduced inventories are number return in and the we the the revenue our we to able in at were recorded is $X quarter. the again. pricing million to around to XXXX and that wholesalers QX charge when OMIDRIA difference ramp majority million hospitals. fourth first sales we because sold answer the XX last quarter both sales returned if nearly vial is our we be recapture expect accounting uncertainty million the Also ASCs QX same in than revenue $X fourth XXXX related held last in QX. of to inventory unit a for in expect Both up quarter
selective basis sales uncertainty regarding suspending most have A QX and customers at are OMIDRIA only. resolution And Given separate payment the reduced use substantial for product are on majority employing been in our ASCs OMIDRIA, a reimbursement. or largely awaiting of regarding hospitals. both
clear, issues, we is broad the for There or We legislation. we One option question OMIDRIA facilities that OMIDRIA. until we decide corporate the payment return will expect for restored for viable. be persist implement of previous how this will bicameral, to payment multi situation to remain alternative way, expect have strategy. OMIDRIA once until to utilization resolved been Either separate customers for extension, has this January into will we the be selling X have to through directed support separate ongoing our drugs been period and support selling in extends organizational prospect years, and to continue, in we the pass pass opportunities bipartisan, address of To this and is for legislation growth through expired Congress near-term There X law. provision that we apply from that But for to senate in Congress house passed would would enact other and through expect for resolution. for which to as legislation already continuing and recently are which pass included procedural to introduced efforts the the OMIDRIA X.
a the with a is drug fee. a It's Another the a packaged procedure, integral a therapeutic outcomes. CMS potentially packaged at and not are is to used CMS a we fix lap, gown, patient. separate improves specific a surgical by individual a drape as on characterizing it OMIDRIA is are drug of that surgical meaning an inaccurate. the indication characteristics the a necessary based as FDA-approved sponge by is part surgical that and that something surgical ensure and for supply. supply OMIDRIA It glove, is route that rates of reduces pursuing drugs of A characterization surgeon currently a complication OMIDRIA direct administrative discretion is other the to payment procedure This is has an supply. that
patient use cost expansion that and and reduced measures point policy. that among to OMIDRIA savings, alternatives of have greater case pupil access needing Congress surgeons physicians from reasons safety, outcomes, like urging the their a of include pass-through the lack CMS as to the letters, on Our lost children that and of underscore by and such and outcome rates, that movement is the calls CMS both messages reimbursement patients products have associated as continued to are by out email ongoing been improved Medicare understand to by and patient has discussions suitable problems of for have We innovative phone well improving that's patients decrease OMIDRIA, its a to are They for are There innovative administrators and difference agency. both are the of CMS restoring In to ensure other their urging patient and exposed this access access leading and certain, seen members ardent devices topic. safety Medicaid, to to status. OMIDRIA absence makes beneficiaries continued appreciative a and OMIDRIA, societies and drugs for important administrators support complication our the facilitate provide with OMIDRIA their by and by why access providing the that patients being drugs the payment. One which and professional patient slew clear of they received encountering patients have in them reimbursement. products we It's to nationwide separate physicians take to to that is OMIDRIA heard customers major for Congress And and thing are adults OMIDRIA. is risks from and good of insured
in we So no the there payment while guarantees for recently near are optimistic term and drugs will OMIDRIA for came off that be that restored other separate pass-through. remain
to pursuit one published OMIDRIA pre to and demonstrating journals. delivery investigator-initiated These the Four of studies with OMIDRIA have during superior unsuccessful, for OMIDRIA, like While reimbursement, soon Physician's clarity of lawmakers strategy. products OMIDRIA expanding improved as phenylephrine facilities has CMS preoperative publications and superior sales cataract OMIDRIA current maintenance that ketorolac in facilities. best own respect OMIDRIA, independently we more which surgery. during four, our year. in and sell progress way OMIDRIA for reimbursed, based published cataract in and/or XXXX have and separately physicians peer-reviewed should and that the our in the payment been were outcomes mentioned not already both approach OMIDRIA better diameter. with practices OMIDRIA. use we patients, post-operative made I And patient recognizing and the an cataract is our awaiting to this and surgery./ and Two, preclude that topical earlier to have Should intra-operative been will pupil compared payment benefits studies and rates consistently then implement alternative detailing reduces The studies that we on of both drugs shareholders Two interest clarity on urging is the standard affecting of administration nationwide benefits, need during are seen OMIDRIA in selling or confirmed reimbursement for published these effective administrators may are OMIDRIA previous surgery. performance be drugs as will manuscripts is the that proved practices. and outcomes provided. been of compared separate complication and toward clinical that uncertainty of in of OMIDRIA our separate their shareholders. physicians given OMIDRIA devices outcomes immediate obtained conducted restore of believe is case And of that be Three, meaningfully NSAIDs the the shown the pupil end, that used investigators in and that
the One epinephrine time, to complication of compared with OMIDRIA the studies examined acuity irrigation solution. and visual surgical to rates added
superiority For all OMIDRIA variables the over of showed epinephrine.
used. when use of pupil OMIDRIA author used, time in used, devices. When of OMIDRIA The reduced devices. OMIDRIA a was be XX% epinephrine an meeting to none other When study was an at looked expansion the expansion group expansion was devices. patients surgical of risk required also was substantially at pupil of pupil patients above deemed required the found The that
of data In children. disclosing populations our & and Without OMIDRIA these of now children. the approved six with patients the Omidrian in in adults US of to for syndrome and to meetings include indicated with in accepted seen intraoperative for Refractive use iris quarter, by label laser were Cataract OMIDRIA Together American the coming addition In of for at second expansion, NDA from Society directed exclusivity. Surgery supporting assisted prematurely are granted months undergoing market And investigators. FDA label investigators patient presentations, in the to fourth the use both cataract expansion is presentation studies for published femto FDA additional other the new OMIDRIA abstracts the floppy supplemental new April. patients those surgery, these
year flow to equivalents. let's financial in cash we cash current turn were we our condition. million And $XX.X had At the nearly end, and quarter, fourth breakeven. for cash Now
million there another at misrepresentations, or intentional covenants $XX.X whether our which were our to of under public that outstanding innocent have confusion been ability CRG comply Recently, $XX.X collected loan million we regarding and receivables with to addition agreement. In year-end.
met F For will only royalties. occur is The but XXXX, OMIDRIA. requirement in to of capitalization for required the that assessment This irrelevant and solely XXXX. XXXX. market exceeded of XXXX the is through agreement late calculated as not milestones, for revenue including March early amount Our cap annual February and such GAAP capitalization revenue loan to annual fees, a XXXX either partnering minimum not each grants a us the amount clear, revenues, revenue satisfy also sales respect year only threshold. overall licensing related be but using To minimum requires applicable or to requirement date the we market market revenues if sales means product even from with or
We have funds. which to May the these any an with XX, ability to to CRG the date to under by customary sole subject of additional $XX our we conditions. Earlier million facility this closing credit CRG discretion or all additional agreed borrow up Omeros' at to borrow can week, extend
So OMIDRIA, of desire on physician of and behalf their benefits the in patients access has clear product been the their of summary, stronger. recognition to never
Our can and we capital is access position solid, financial discretion. additional at our
regarding reimbursement uncertainty then be to the utilization remain continue confident in resolved again. OMIDRIA will that CMS you expect up pipeline. fuel soon our ramp and that help will will OMIDRIA We for XXXX quickly We
MASP-X of to our key lead pathway MASP-X targets program and MASP-X of immune of complement now that turn Let's includes our OMSXXX inhibitors system, with the a component the lectin response. complement OMSXXX. which the OMSXXX franchise starting our pipeline
syndrome Phase cell We stem or cell underway three IgA Immunoglobulin TMA. And stem aHUS. OMSXXX. with A, or uremic X or hematopoietic programs atypical thrombotic transplant-associated have hemolytic clinical microangiopathy, nephropathy;
the proteinuria. only ongoing on OMSXXX have a which generate OMSXXX concurrence In alone. diseases, that OMSXXX nephropathy, breakthrough for other and OMSXXX single in could two one drug receive has to in our only X is cell X our program renal study approval data. is each lead Phase agreed be on with of has and the clinical have proteinuria FDA for stem clinical positive continued design approval drug IgA reached trial FDA's to also To with full Phase and We could in Phase therapy the TMA that designation which patients granted X on nephropathy. trials, first the full FDA IgA knowledge based we to first in reduction
or partial the who depending after responders for is trial the design fallback, the could day also dose per drug a the randomized one XX for in includes reduction is IgA weeks p-value dosing other XX As in endpoint renin-angiotensin weekly to mentioned of administered double-blind will week effect can weeks, XX I excretion XX and primary nephropathy sample RAS a biopsy start an patients patients age X on urine and additional alpha. adaptive structured IV single for or specifically words, of path dosing. without as for required to at system be proteinuria on level relapse. with years optimized approval, accelerated trial gram The that a blockade. affecting least X of Initially spending trial, protein full which multi-center confirmed Phase allow Phase at adjustment size suffice significance. intra The greater In an for trial employ receive each trial is the approval size of study at with without hour placebo-controlled statistical baseline than design patients
XXX levels grams of for size baseline for groups. This proteinuria approval. subset a high equal than in day of of of each alone substantial the could a high-protein with will patients proteinuria and endpoint form at the patients include to this or itself purposes defined weeks per and greater treatment in sample subset estimated as efficacy at the For two safety is basis XX and initial at the placebo patients assessments, of improvement
a And there proteinuria the on based accelerated high weeks study So for in to four, In Two, patients. positive of population nephropathy group based approval approval could be weeks data. in XX in XX of in approval across the subset are general approval the data. in on based patients. proteinuria week of the accelerated XX available high patient One, achieve full Three, based the proteinuria ways on full proteinuria the accelerated again population Phase subset proteinuria treatment week proteinuria general approval event on this X XX of at made IgA trial. patients. OMSXXX commercially either four outcome
or disease-modifying trial we approval clinical IgA of patients estimated our trial glomerular to Patient measure XXX in X initiate second a significantly enrollment sites potential the our proteinuria. high approval could added trial weeks, OMS alone continue renal proteinuria in would enroll option X study the include OMSXXX; function. patients solely would are of filtration in phase likely at would indicated pursuing EGFR, on require market, assess IgA IgA additional would a likely this require to internationally. with Phase XX fewer more population; full rate trials, clinical receive While are on focused change even satisfactory approval patient trial data data we that a than underway and OMSXXX is planning This biopsy an third general FDA full US being achieve also and the XX clinical Because proteinuria on that would quickly broader than and the week alone. in provide full would to a
patients provided in company FDA this options. Hong has this In US addition, Kong, the trial option this evaluating nephropathy a not includes which past even we're we open-label believe US that trial portion dosing mid-year. only XX the controlled could underway market trial the from steroids. and retreatment faster cohort Data placebo X expected and indication Phase if OMSXXX to follow-up provide an The is for of and of In are double-blind needed. with the taking extended and weeks the the IgA
low with baseline are in As also EGFR. study we a patients we reported, planning previously
that would We stage rapidly that disease have dialysis. in in renal this OMSXXX reason to is be population believe effective and approaching
week drug designation the drug in In just EMA nephropathy same for to designation indication. confirmed from for designation addition and has received therapy breakthrough OMSXXX orphan FDA IgA orphan this OMSXXX
receive prime; A pursuit program, the prime breakthrough our we or for designation IgA nephropathy. also of from by does prime EU. to incremental therapy prime timeline primary in for affect afforded our pursuing orphan planned OMSXXX EMA's already designation through EMA newer approval in of IgA. pursuing shorten can incentives in in that timeline fee EMA's priority conditional OMSXXX accelerated the receive obtain the incentives is medicines US, FDA's advantage Unlike to fee in which for given We are not approval program most
a in transplant with total patients February, study cell control. under TMA these stem estimated patient To to program with patients with OMSXXX has protocol. reported we historical TMA additional treated of X a progress. TMA with use compassionate have and an stem cell one been Phase OMSXXX. matched on in XX date, In generated also XX exciting a treated evaluating in and ongoing the cell stem increase survival Our overall patients best compared data demonstrating median patients OMSXXX associated
using of platelet a cell patients. was leukemia, XX were low and matched myeloid days stem-cell And the were by demonstrated this for of red red less acute the with p-value Not best X.XXXX median stopped publicly, production an of receiving cell either estimated saw it stopped these significant in the XX and of study X OMSXXX. the malignancy OMSXXX only and we ongoing died a severe requirements study X blood blood had group of control transfusions thereafter. treated Kaplan-Meier platelets. in The treated characterized markedly versus than or reduced OMSXXX a bone To or patients come survival. X significant received patient XX completely at days anemia log-rank shortly X discontinued improvement entry. - XXX group TMA test. also The median the patients by overall than in transfusions two of doses survival fold put time discussed the the marrow either patient treated OMSXXX patients analysis greater was transfusion previously for Specifically overall improvement estimated the these simply, patients in
all or patients cell meaningful activity treated and improvements dehydrogenase lactate TMA continued to LDH significant count platelet markers the OMSXXX. with of statistically the assessments clinically TMA and in stem of updated globin addition, demonstrate In half
who patient experience and abuse discontinued and OMSXXX TMA not one was of hemodialysis hemorrhage discontinued to following oxygen treatment. doing respiratory discontinue and alveolar eculizumab tolerate last At did report, well. reported, previously in was resolution support, treatment home She initiation she transfusions. As of able platelet
study to history transplant treatment bedridden and his stem of TMA emerging type resolved include steroid that graft-versus-host and the GVHD OMSXXX work. with removing neurological occlusive OMSXXX Another different him community with cell or targets. many by diffuse presented GVHD transplant the improved multiple refractory These with the markedly, to vino stem state with alveolar injury patient injury, part-time the endothelial his, and GVHD and function driven complications of following endothelial abnormalities, syndromes view from a results him TMA disease disease returning exactly cell neurological These so that are consistent in OMSXXX injury hemorrhage. are called and coexisting TMA cell GVHD
you results transfusion biomarkers, we are and look requirements both authorities overall relevant OMSXXX that median survival, and in US patient across anyway regulatory to with in them or and discussing whether of assess by Europe. course, So forward TMA, cell the by clinical the data compelling the consistent stem and
As the in concerns X trial OMSXXX date, been in tolerated safety no has identified. clinical with drug TMA every well trial the to Phase
during progression one FDA's because definitively stem and and recently OMSXXX occurred association designation be submitted transplants the out deaths due request, common study, acute could renal only of investigator. therapy neutropenic in these of for a we to application and TMA. one OMSXXX was considered stem of due respiratory drug-related of respiratory FDA the to to is Three hematopoietic full possibly deaths renal acutely not or acute the not For cell to ruled to breakthrough an failure cell which sepsis myeloid complication At deaths be a and by were failure. related deemed to leukemia; due these one two:
discuss OMSXXX approval, accelerated to the are the expeditious of with this most possibility We meet to including for in pathway approval to indication. scheduled FDA
regulatory including discuss requesting meetings We within also in authorities conditional the to approval approval pathway forward Europe. the are EU with to
as are exploring We our well. major and options markets other
first In Our clinical subcutaneous a enrolling intravenous dose clinical XX OMSXXX internationally. trial treatment program week, X of loading control arm. open-label consists targeting and the in no two other an Phase The arm. regimen together is with X simple a weekly dosing. aHUS patients consists approximately of program with single words, only Phase
Our primary assessed endpoint XX weeks. will to be
aHUS enrollment treatment XX in have Europe designation for drug required approval full designation from XX with Our for full another for granted we've in received aHUS. patient To target FDA's US approval TMS satisfy and track could also patients the approval. provide orphan patients FDA the for of been accelerated with the date, fast broadly and requirements FDA's including
administration, we small MASP-X also selective cocrystallization; and of Our variety number program potent of molecule oral molecules. tools includes using generated for MASP-X inhibitors a have including highly a
we to the Our clinic. optimizing as are medicinal chemists advance them
Any be lead to our an complement the expression Antibody MASP-X Our will as also that and MASP-X. paroxysmal delivered for early alternative in fair Omeros be the alternative underway pathway. progress currently key linked the product has scale-up to antibody enter good indication. MASP-X our our as of expect late targeting MASP-Xinhibitors. targeting the antibody PNH readily to to candidate. clinic to franchise system We hemoglobinuria in complement Omeros or the or manufacturing been includes for XXXX initial formulations program concentration we first pathway plan OMSXXX high XXXX was subcutaneously. continues nocturnal achieve and and are robust comfortably make activator indication game the with identify should clinical
briefly now on includes our progressing MASP-X few a program of As or molecule rapidly. highlights program, I'd like with other two programs our to are OMSXXX pipeline to small financial our and on MASP-X results. we some these inhibitors, move provide before
system dopamine the OMSXXX controls inhibitor be compulsive compulsive play is addiction any the of work we addiction. of a in through central X the is any PDEX use field again programs will phosphodiester our addiction to PDEX through treatment for exclusively to our of known which lead PDEX turn disorder. inhibitors or the Omeros let's believe where inhibitor. First, role. disorders Omeros or and major
has alcohol, well and OMSXXX cocaine, as animal results opioid models consistently generated addiction, in of program Our positive as in nicotine eating. binge
could hinders reward that the both currently any agents. seriously approved inhibit relapse system. use translate animal addiction. addiction all Q does not A forms and in humans, of decreasing addition Should data the depress first craving, In OMSXXX the OMSXXX stress-induced be of to to the drug treat problem but
Our program trial initiate OMSXXX X Phase clinical remains to on mid-year. by our track
We we unmet addiction target there remains a will expect need. that initially which for nicotine substantial
also Phase in addition X while Pharmacology, been our conducted program trial agonist OMSXXX had use investigators In the data nicotine Biochemistry focused inhibitor data published generated published PPAR-gamma X data. our journal cocaine clinical positive to on from The Phase by the journal the in disorder a PDEX have from been in Addiction, has a study independent and Behavior.
The exclusively ranging Omeros dose. that In GPCR submitted heroin addition, dosing from Phase that analysis or with FDA to clinical PDEXX, wrap will we program. findings for allow a resulting our have XX, of cancer, up program, central XX specific with differences discussion development the a system manuscript this pipeline continues in nervous been discussed analysis the that data broad limited of In disease the believes with publication in inform clinical results resumption disorders. for with cardiovascular indications, it the journal. a our limitation. is be controls X of OMSXXX data may peer-reviewed in and program well. study progress including without GPCRs species Work has inhibitor as We'll metabolism, phosphodiesterase
the and in interleukin are regulatory T-cells in mononuclear PDLX. promoting cells previously program are the These sarcomas increased inhibitors necrosis GPRXXX including targets, accelerating our cytokines and noted, molecule on amphiregulin. X CTLA T X data and the levels expanded a and the number gamma protein cancer tumor ligand small of compounds blood factor-alpha medicinal Treating reduced and associated vivo capabilities our X, X GPRXXX immuno-oncology. checkpoint It for human have with of As we XX, the or optimization. interferon and breast cytotoxic across and the peripheral interleukin generating decreased positive death progress GPRXXX of lymphocyte of for triple of levels chemistry or compound resulted negative levels tumor also number protein our factor
cancer critical appears To So the affects our pathways time functions inhibiting GPRXXX Omeros entity and inhibitors. GPRXXX while for target and singly suppressive cancer functions GPRXXX system, other constraining constellation treatment. all the other this knowledge immune same no its stimulate of has at than no to related
other and build a targets. We to around on continue end the of our update With this and turn a estate call programs summary products over to fourth-quarter our GPCR the property that financial Mike Omeros' broad I'll and intellectual for results.
